Launch Blue Announces Third UAccel Cohort
August 30, 2021
Launch Blue is pleased to announce the Fall 2021 UAccel University Technology Commercialization Focused Cohort. Thirteen technologies from Kentucky universities were selected to participate in the 12-week UAccel program.
UAccel is a Launch Blue cohort organized in partnership with the University of Kentucky Office of Technology Commercialization and Kentucky Commercialization Ventures. The program is designed to offer professional development and an experiential learning opportunity to innovators in higher education interested in learning the best commercialization path for their technology. The goal of the program is to advance the technology toward commercialization, including preparations for Small Business Innovation Research (SBIR) grant applications, the creation of a startup, or licensing of the technology.
Candidates were selected through a competitive application and interview process. The final selections for the cohort were determined by a selection committee appointed by the organizing partners. Applications for the Spring 2022 UAccel cohort will open in November 2021.
Participants in the Fall 2021 Cohort are:
A single- and multi-player virtual game involving a multi-station production line that can be transformed into a just-in-time manufacturing system by applying lean tools and techniques. The innovation will offer a versatile, cost-effective, and easy-to-use tool to increase student engagement and effectively teach lean concepts in the online environment and also complement in-person learning.
A platform to address data management inefficiencies in State agency daily operations, focusing is the centralization of data, forms, and reports while streamlining the most common tasks. The goal is to significantly reduce the time of data management and research tasks, allowing agents greater opportunity to perform other critical job functions.
A novel app for mobile and wearable devices to track motion during resistance training. The clinical goals are to optimize adaptations to exercise and limit risk of acute injury and overtraining.
The MedSkin artificial skin was created to address the problem with the lack of realistic, anatomically accurate low-fidelity task medical trainers that are also multifunctional, durable, portable, and reusable.
Surgeons and endoscopists encounter bleeding frequently during endoscopic operations costing time, money, and even the success of the operation itself. This medical device will revolutionize the level of bleeding regulation during these procedures to bring control back into the hands of the physician.
Hydrophobic natural deep eutectic solvents (NADES) are a cheap, non-toxic, and easy to synthesize class of solvent that has shown to be effective in extracting micro-and nano-plastic particles from water. This could be utilized by micro-and nano-plastic researchers to detect plastic in water samples more efficiently or to separate plastic from other contaminants.
Acoustic driven packing material can increase the absorption rate of liquid-gas chemical absorption process, such as CO2 capture, by up to 40 percent. This can substantially reduce the initial capital costs of certain chemical processes and make the adoption of CO2 capture technologies more feasible for affected industries.
The current COVID-19 pandemic has brought health, economic, and social difficulties to all communities of the world. While existing commercial respiratory face masks do exist, such as N95 masks, their protection is not absolute and there exists an immense need for technological improvement. This technology allows for the development of an individual face mask with greater virus particle filtration efficiency and less skin irritation from use than existing products while having the ability to deactivate virus particles that encounter the mask, furthering the protection of the individual from infection.
An interactive platform for extraction, harmonization, management, and utilization of big data from electronic health records and dialysis devices to improve the quality and delivery of dialysis in critically ill patients admitted to intensive care units.
Therapeutic for postoperative pain management and inflammatory disease.